1. IVF protocol efficacy in women with expected suboptimal response depending on ovary stimulation mode.
- Author
-
Ob'edkova KV, Kogan IY, Muller VC, Tapilskaya NI, Krikhely IO, Dzhemlikhanova LK, Abdulkadirova ZK, Mekina ID, Lesik EA, Komarova EA, Ishchuk MA, and Gzgzian AM
- Subjects
- Adult, Female, Humans, Oocyte Retrieval, Pregnancy, Pregnancy Rate, Recombinant Proteins administration & dosage, Treatment Outcome, Fertilization in Vitro methods, Follicle Stimulating Hormone, Human administration & dosage, Menotropins administration & dosage, Ovulation Induction methods
- Abstract
Investigation Objective: IVF protocol efficacy estimation in women with expected suboptimal response depending on ovary stimulation mode., Materials and Technique: A randomized controlled study embracing results of 51 IVF cycle in women with ovary suboptimal response. The suboptimal response prognostic analysis was performed basing on ≤9 oocyte cumulus complexes obtained in previous IVF programs, the presence of no less than 5-9 antral follicles in both oocytes and amount of anti-Mullerian Hormone ≥0,8 ng/mL. In Group I ( n = 25), the stimulation was performed by recombinant corifollitropin alfa combined with highly purified urinary gonadotropin, while in Group II ( n = 26) it was made by means of recombinant follitropin/lutropin alfa within the protocol of applying gonadotropin-releasing hormone antagonists., Results: The total gonadotropin dose in Group II patients was authentically lower compared to Group I ( p ˂,01). No statistical difference between the two studied groups was detected concerning the number of obtained oocytes, 2pn zygote, good-quality transferred embryos and clinical pregnancy rate ( p >.05). Embryo cryopreservation was performed only for group-II patients., Conclusion: Corifollitropin alfa administration combined with highly purified menotropin in IVF cycles for suboptimal responders is quite effective, however, this strategy has no preference over other stimulation modes. The strategy of using recombinant follitropin/lutropin alfa can be promotive to IVF outcomes for suboptimal responders by means of embryo banking. ClinicalTrials.gov Identifier: NCT03177538.
- Published
- 2021
- Full Text
- View/download PDF